Dr. John DeGroot
Dr. John de Groot is a Professor in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He is an expert in the fields of glioma angiogenesis and molecularly targeted therapy. He completed his medical education at The University of Texas Medical Branch at Galveston, and pursued internship and residency at Johns Hopkins School of Medicine. Following a clinical fellowship at MD Anderson, de Groot joined the faculty in 2004. His translational research program has produced critical insights into how gliomas respond to and resist killing by anti-angiogenic agents and illuminated therapeutic approaches employed in clinical trials to overcome this resistance. De Groot has also significantly contributed to the discovery of biomarkers of response and progression in glioblastoma patients treated with anti-angiogenic therapy, and as a result has opened multiple biomarker-driven clinical trials.
John deGroot, MD, Neuro-Oncologist at MD Anderson
Dr. de Groot has served as the principal investigator (PI) or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants. He is the PI of numerous clinical trials involving novel agents being tested in patients with glioblastoma and is a co-leader of the MD Anderson GBM Moon Shot program. Dr. de Groot has over 140 peer-reviewed articles. He is or has served as a peer reviewer for 23 scientific journals and is on our editorial review boards. As a professor within the Department of Neuro-Oncology, he has direct influence on the teaching of the next generation of clinician scientists.